Psychosis – Pipeline Review, H2 2012

Psychosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Psychosis - Pipeline Review, H2 2012', provides an overview of the Psychosis therapeutic pipeline. This report provides information on the therapeutic development for Psychosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychosis. 'Psychosis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Psychosis.
- A review of the Psychosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psychosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Psychosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Psychosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Psychosis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Psychosis 7
Psychosis Therapeutics under Development by Companies 9
Psychosis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Psychosis Therapeutics – Products under Development by Companies 15
Psychosis Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Psychosis Therapeutics Development 17
H Lundbeck A/S 17
NeuroSearch A/S 18
ACADIA Pharmaceuticals Inc. 19
Mayne Pharma Limited 20
Psychosis – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Zicronapine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
BVF-036 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 30
NSD-847 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Valtrex - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Ziprasidone - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Risperidone - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
THC + Lomazenil - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BVF-040 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Psychosis Therapeutics – Drug Profile Updates 37
Psychosis Therapeutics – Discontinued Products 39
Psychosis Therapeutics - Dormant Products 40
Psychosis – Product Development Milestones 41
Featured News & Press Releases 41
Apr 19, 2010: Mylan Launches Clozapine Tablets USP, 50mg And 200mg In US 41
Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting 41
Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis 42
May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 42
Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 43
Dec 19, 2003: Lundbeck Initiates Phase I Clinical Study Of Lu 31-130 For The Treatment Of Psychosis 43
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Psychosis, H2 2012 7
Products under Development for Psychosis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
H Lundbeck A/S, H2 2012 17
NeuroSearch A/S, H2 2012 18
ACADIA Pharmaceuticals Inc., H2 2012 19
Mayne Pharma Limited, H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Psychosis Therapeutics – Drug Profile Updates 37
Psychosis Therapeutics – Discontinued Products 39
Psychosis Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Psychosis, H2 2012 7
Products under Development for Psychosis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26